Twist Bioscience legal chief sells 412 shares

Twist Bioscience’s chief legal officer sold shares only to cover tax withholding on RSU vesting, retaining over seventy-three thousand shares.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 412 shares of common stock on September 8, 2026 at $122.62 per share. According to the company’s disclosure, these shares were sold solely to cover tax withholding upon vesting of Restricted Stock Units, and were not discretionary trades. After this transaction, Cho directly held 73,651 shares of Twist Bioscience common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 412 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 412 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	412	$122.624	$51K

Holdings After Transaction: Common Stock — 73,651 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 412 shares Sale price per share: $122.62 per share Shares held after transaction: 73,651 shares

3 metrics

Shares sold 412 shares Common stock sold on September 8, 2026 to cover tax withholding

Sale price per share $122.62 per share Price for the 412 shares of common stock sold on September 8, 2026

Shares held after transaction 73,651 shares Direct holdings of Dennis Cho after the September 8, 2026 sale

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans

3 terms

Restricted Stock Units financial

"tax withholding obligations in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"funded by a "sell to cover" transaction and do not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"the Issuer's election under its equity incentive plans to require"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

What insider transaction did Twist Bioscience (TWST) report for Dennis Cho?

Twist Bioscience reported that Dennis Cho sold 412 shares of common stock on September 8, 2026 at $122.62 per share. The company states the sale was required to cover tax withholding on vested RSUs under its equity incentive plans.

Was the Dennis Cho sale in TWST stock a discretionary trade?

No. The company states the 412 shares were sold to satisfy tax withholding obligations related to vesting Restricted Stock Units and describes these as mandated “sell to cover” transactions rather than discretionary trades by Dennis Cho.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after this transaction?

After the September 8, 2026 transaction, Dennis Cho directly held 73,651 shares of Twist Bioscience common stock, according to the company’s disclosure.

What was the sale price for the Twist Bioscience (TWST) shares sold by Dennis Cho?

The 412 shares of Twist Bioscience common stock sold by Dennis Cho on September 8, 2026 were reported at a price of $122.62 per share, characterized as a sale in the open market or a private transaction.

Was Dennis Cho’s September 2026 TWST trade under a Rule 10b5-1 plan?

No. The company’s filing indicates the Rule 10b5-1 checkbox was not selected, and there is no statement that the September 8, 2026 sale was made under a Rule 10b5-1 trading plan.

What role does Dennis Cho hold at Twist Bioscience (TWST)?

Dennis Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, as stated in the company’s disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:00 PM Accepted by SEC EDGAR 09/10/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S		412(1)	D	$122.624	73,651	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)